Update: On January 3, 2024, the Medical Devices Regulations were amended to broaden the scope of the UPHN list beyond COVID-19, to apply to future public health emergencies.
On February 22, 2023, amendments to the Medical Devices Regulations (Regulations) came into force that create a permanent regulatory framework for COVID-19 medical devices: Regulations Amending the Medical Devices Regulations (Interim Order No. 3 Respecting the Importation and Sale of Medical Devices for Use in Relation to COVID-19) (see also Health Canada’s notice and guidance).
To expedite access to COVID-19 medical devices, the Minister of Health made the Interim Order Respecting the Importation and Sale of Medical Devices for Use in Relation to COVID-19 in March 2020 (previously reported). This was repealed by the Interim Order No. 2 Respecting the Importation and Sale of Medical Devices for Use in Relation to COVID-19, which was in turn repealed by the Interim Order No. 3 Respecting the Importation and Sale of Medical Devices for Use in Relation to COVID-19 (previously reported) (the Third Interim Order).
The amended Regulations are intended to maintain flexibilities and active authorizations granted under the Third Interim Order. Under the amended Regulations, Health Canada will publish and maintain the List of Medical Devices for an Urgent Public Health Need in Relation to COVID-19 (UPHN List). Authorization holders for medical devices on the UPHN List are granted regulatory flexibilities similar to those provided by the Third Interim Order (e.g., for manufacturers, this includes exemption from certain licence requirements under the Regulations). Authorizations granted under the Third Interim Order will remain in place under the amended Regulations, although additional requirements are triggered once a device is no longer on the UPHN List.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
On April 1, 2024, the fee for filing a Certificate of Supplementary Protection (CSP) will increase from $10,152 to $10,356.Read More
A proposed program by the state of Florida to import certain prescription drugs from Canada has received the approval of the United States Food and Drug Administration (FDA): FDA news release on Janua...Read More
On January 3, 2024, Regulations Amending the Medical Devices Regulations (Medical Devices for an Urgent Public Health Need) came into force.Read More